TriangleHEALTH PROFESSIONAL · SOURCE READING
Watchful waiting/active surveillance
Source: Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: February 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Nodular Lymphocyte–Predominant HL (NLPHL) / Treatment Options for NLPHL
Because of the favorable prognosis for NLPHL and the potential long-term side effects of therapy, studies have evaluated watchful waiting or active surveillance for patients with asymptomatic, low tumor burden disease.[9] In a retrospective comparison, 37 such patients managed with active surveillance had a 5-year progression-free survival (PFS) rate of 77%, versus 85% for patients receiving active treatment.[10][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice